Priya Garg

The INTERACT study: Infection prevention and surveillance practice in the care of the Australasian cancer and transplant population Australasian cancer and transplant populations are expanding, with increased infection risk related to prolonged survivorship and broader use of novel immunosuppressants. To optimise care, standardise...

Pleased to publish the INTERACT study - describing current infection prevention & surveillance practice in the care of Australasian cancer/transplant patients & areas for future research (& thankful to all who participated) 🌟 @ncicancer.bsky.social #TxID #IDSky

www.ajicjournal.org/article/S019...

Our new @txidfellows.bsky.social paper is out! This one on ASP in #TxID. Practical tips for beginners and early career faculty. @courtharrismd.bsky.social @rebeccakumar.bsky.social @divsharma.bsky.social @mirandapharmdmph.bsky.social @hannah-imlay.bsky.social

The ECIL guidelines are gold!

Delighted to have been part of these important ECiL-10 c diff guidelines specific to our haematology patients.
#TxID @ncicancer.bsky.social @ichs-global.bsky.social @theebmt.bsky.social

www.sciencedirect.com/science/arti...

What a great bunch! 👋🏽

.@astct.bsky.social has #ID #HSCT #CAR-T guidelines in TCT Journal
transplantid.net "GUIDELINES"▶️ "ASTCT Guidelines"📁

#️⃣ 9️⃣ : Mgmt of HHV-6B after HSCT and CAR-T
Bonus: Tests for chromosomal integration!
Thanks Aneela Majeed @clevelandclinic.bsky.social!

transplantid.net/37V7X3QT

Excited to see what the PROSPER study (point prevalence of infections in cancer & transplant) demonstrates.. @ncicancer.bsky.social 🦠 @bmj.com #TxID #IDSky #EpiSky

We were proud to be well represented at the inaugural The
Transplantation Society of Australia and New Zealand Infectious Disease Day on 20 June 2025 — a fantastic event co-badged with ASID Immunocompromised Host Special Interest Group.

Thanks so much for sharing @bradgardiner.bsky.social

Pleased to present our subgroup analysis @TSANZ. Would IPC specific to the SOT cohort be valuable? Which HAIs/OIs should we monitor, and how do we build a national framework for success? @ncicancer.bsky.social #TxID #IDSky

Extremely cold! Even for an ex-Brit 🤣

#TxID #IDSky

Always a pleasure to hear @aussiedocwolfe.bsky.social speak on advances in organ transplantation & thankful to chair a session on infection surveillance in transplant @TSANZ Transplant Infectious Disease day! Congrats to the committee for putting together an exciting inaugural meeting.

Happy Infectious Diseases Pharmacists Day to my colleagues, mentors, and clinician-researcher heroes #IDPharmacistsDay #SIDPAdvocacy @adphaau.bsky.social @sidpharm.bsky.social @ncicancer.bsky.social

We would be lost without you! 💊

#TxID #IDSky #IDOnc 🙌🏽

Grateful to have received a travel stipend to spend an exciting few days at the @fredhutch.bsky.social ICH Symposium in Seattle, present & learn from experts in the field- Including @kottonnelson.bsky.social, Jay Fishman & our own @ncicancer.bsky.social @michyong.bsky.social, Monica Slavin & more..!

Figure 1 Overview of mechanisms of action of different drugs used in the treatment of infection with HSV-1/2. The nucleoside analogues ACV, PCV and BVDU are phosphorylated by viral TK. ACV-P, PCV-P, BVDU-P and CDV are biphosphorylated by cellular kinases. The phosphorylated compounds are then incorporated into nascent DNA. This leads to a stop in viral replication or, in case of BVDU, destabilizes the DNA and inhibits the replication. FOS inhibits replication by directly binding POL and inhibiting the pyrophosphate binding site competitively. AMNV and PTV bind to the viral helicase-primase complex. This inhibits DNA unwinding and therefore inhibits replication. ACV: aciclovir; PCV: penciclovir; BVDU: brivudine; CDV: cidofovir; FOS: foscarnet; AMNV: amenamevir; PTV: pritelivir.

Herpes Simplex Virus and Drug Resistance - Comprehensive Update on Resistance Mutations and Implications for Clinical Management: A Narrative Review

Open Access @cmijournal.bsky.social

www.clinicalmicrobiologyandinfection.com/article/S119... #IDSky #TxID

A line graph illustrating immunosuppressive drug intensity and immune cell recovery (CD4+ T, B and NK cells) over months following kidney transplantation, highlighting a window of heightened cryptococcal disease risk.

Two parabola diagrams comparing HIV-associated cryptococcal damage and non-HIV transplant-associated damage. In both settings, too little or too much immune response can result in host damage (left and right arms of the parabola). However, in non-HIV transplant patients, the overall position on the parabola is less predictable, due to the heterogeneous effects of immunosuppressive medications before and during cryptococcal infection.

Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the need for Individualized Immune-Based Strategies

Hyunah Yoon, Liise-anne Pirofsky, @drboulware.bsky.social

In non-HIV-associated CM, ⬇️ing immunosuppression --> ⬆️ inflammation --> 🧠 damage.

academic.oup.com/cid/advance-... #TxID #IDSky

New from @loukasmd.bsky.social et al:

Authors provide systematic review of pathogens & sources of contamination linked to outbreaks in HSCT units

▶️ 39 studies, various sources including water, construction, contamination

#IDSky

📄: doi.org/10.1017/ice....

The most anticipated RCT in ID
🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia
N:1341
Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia
Cefazolin is non-inferior (90d mortality)& less AKI than ASPs
A practice-changer RCT that must change the guidelines
#ESCMIDGlobal #IDSky

📌

📌

📌

Thanks so much @benwteh.bsky.social & for your expert chairing! 🙌🏽

Day 2 of the Australasian Society for Infectious Diseases (ASID) ASM in Canberra, our incredible NCIC team proudly showcased their poster presentations. It was a fantastic opportunity to showcase their hard work and dedication to advancing the ICH space on a national stage!

Great to hear work by my friend, fellow ID physician & PhD candidate @dremmalouise.bsky.social & nursing student Jobe Bonney on tackling TB in remote communities at the ASID ASM - excited to hear how the REACT project progresses! @asidaud.bsky.social

@asidaud.bsky.social

Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽

Great 1st day at Australasian Society for Infectious Diseases meeting!

@michyong.bsky.social led an insightful CMV symposium

@benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG

@priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space